Australia markets closed

Allogene Therapeutics, Inc. (ALLO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
10.96+0.18 (+1.67%)
At close: 04:00PM EDT
11.37 +0.41 (+3.74%)
Pre-market: 08:59AM EDT
Show:
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2021
31/12/2020
31/12/2019
31/12/2018
Total revenue
247
38,489
0
0
0
Operating expenses
Research development
230,030
220,176
192,987
144,535
151,860
Selling general and administrative
78,365
74,105
65,256
57,473
40,982
Total operating expenses
308,395
294,281
258,243
202,008
192,842
Operating income or loss
-308,148
-255,792
-258,243
-202,008
-192,842
Interest expense
-
-
0
0
3,358
Total other income/expenses net
-929
-2,927
-1,142
-268
-21,211
Income before tax
-307,691
-257,005
-250,221
-184,925
-211,622
Income tax expense
-
0
0
-331
-117
Income from continuing operations
-307,691
-257,005
-250,221
-184,594
-211,505
Net income
-307,691
-257,005
-250,221
-184,594
-211,505
Net income available to common shareholders
-307,691
-257,005
-250,221
-184,594
-211,505
Basic EPS
-
-1.89
-2.08
-1.83
-7.31
Diluted EPS
-
-1.89
-2.08
-1.83
-7.31
Basic average shares
-
135,820
120,370
101,061
28,948
Diluted average shares
-
135,820
120,370
101,061
28,948
EBITDA
-
-245,338
-242,635
-179,898
-206,764